oral glp 1 inhibitors GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Orforglipron, an Oral Small-Molecule GLP-1

Sun M, Ye H, Zheng C et al (2023) Astragalin ameliorates renal injury in diabetic mice by modulating mitochondrial quality control via AMPK-dependent PGC1 pathway

doi: 10.1016/j.lrr.2017.03.001 106 LitzowMRLeeSBennettJMDewaldGWGallagherREJainVet al

Lorsque ces cellules taient exposes des concentrations de 0,5% et 1% de L-carnitine, elles prsentaient une augmentation significative de la -oxydation , cest--dire du processus de dgradation des acides gras par les mitochondries

doi: 10.1007/s00223-015-0037-y 14 MabilleauGMieczkowskaAChappardD

They are not intended to represent clinical evidence in humans, and IGF-1 LR3 has not been approved by the FDA, EMA, or any other regulatory authority for any indication

G., Tan, T.-W., Boulton, A